NLRP3 and metabolic dysfunction-associated steatohepatitis: Moreover, Empagliflozin participates in the treatment of NASH by inducing ASC oligomerization to suppress NLRP3 inflammasome activation and inhibit caspase-1 (Van Rooyen et al., 2011).